atepeq/tico19 huggingface dataset:
Few data are available about microscopic lesions and the pathophysiology of COVID-19.
Guyyoonni murtaa’aniin waa’een madaa xiqqoo fi daddarbiinsa COVID-19 argamuu mala.
The main pathological findings at autopsy are:
Qorannoo dhibeewwanii warra du’an irratti taasifame argannoowwan isaa guddaan isaan kana:
Macroscopy: pleurisy, pericarditis, lung consolidation and pulmonary oedema
Maaykirooskooppiin: hubamuu golga sombaa, jajjabaachuu sombaa fi babaldhachuu sombaa.
Four types of severity of viral pneumonia can be observed:
Vaayirasiin michii sombaa cimaan akaakuu afurtu argame:
mild pneumonia: pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation
Niimooniyaa salphaa: dhiita’uu kalee, niimosaayit hayperpilashiyaa, niimoosaayit guddaa, tishuulee gidduutti dhiitofni uumamuu fi seeliin niwuukilasii hedduu qabu baay’ee guddaa ta’e uumamuu.
severe pneumonia: diffuse alveolar damage (DAD) with diffuse alveolar exudates.
Daranyoo sombaa hamaa: miidhaa tatamsa’aa ujummoo qilleensaa xixiqqaa (DAD) dhimmisa ujummoo qilleensaa faffaca’aa wajjin.
DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.
‘DAD’ sababa mallattoo ukkaamfamuu hafuuraa hamaa (ARDS) fi hir’ina ooksijiinii dhiiga keessaa hamaati.
healing pneumonia: organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis
Niimooniyaa dandammii: qindaa’ina dhuujummooafaan keessaa fi dhuujummoo onnee keessaa gudduu
Blood: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction
Dhiiga: dhiigi faffaca’ee hidda dhiigaa keessatti kantaruu (DIC); luukoo’eeriitiroobilaastik ri’aakshinii
Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene and avoiding touching the eyes, nose or mouth with unwashed hands.
Carraa dhukkuba kanaan qabamuu hir’isuudhaaf tarkaanfiiwwan ittisaa mana keessa turuu, bakkee namni itti baay’atu irraa fagaachuu, irra deddeebiin harka saamuunaadhaafi bishaanii yoo xiqqaate sekoondii 20 f dhiqachuu, qulqullina hafuura baafannaa gaarii shaakaluu fi ija, funyaan, yookaan afaan keenya harka hindhiqamneen tuquu dhiisuufaa of keessatti qabata.
The CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available.
CDC’n yeroo qufaanuu fi haxxifannu harkaa fi afaan keenya akka ciqilee harka keenyaatiin haguugnu dhaama.
Proper hand hygiene after any cough or sneeze is encouraged.
Qufaa yookaan haxxifuu kamuu booda qulqullina harkaa sirriin barbaachisaadha.
The CDC has recommended the use of cloth face coverings in public settings, in part to limit transmission by asymptomatic individuals.Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel and cancelling large public gatherings.
Namoota mallattoo hin agarsiifne irraa gara isa kaaniitti akka hin daddabarre CDC’n naannawa ummanni baay’inaan argamutti uffataan fuula haguuggachuu ajaja jira. Adeemsi addaan siiquu hawaasaa manneen barnootaa fi iddoo hojii cufuun, imala ugguruunii fi walitti qabama ummataa hir’isuun waltutuqqii nama dhibichaan qabamee fi hawaasa fayyaa gidduu jiru hir’isuuf kan kaayyeffateedha.
Distancing guidelines also include that people stay at least 6 feet (1.8 m) apart.
Qajeelfamoonni wal irraa fagaachuu namoonni yoo xiqqaate fiitii 6 (meetira 1.8) ni dabalata.
There is no medication known to be effective at preventing COVID-19.As a vaccine is not expected until 2021 at the earliest, a key part of managing COVID-19 is trying to decrease the epidemic peak, known as "flattening the curve".
COVID-19 ittisuuf qorichi bu’a-qabeessa ta’uun isaa beekame hinjiru. Yoo baay’ee dhiyaate hanga 2021 tti talaalliin waan hin yaadamneef to’annaa COVID-19 tiif furtuu kan ta’an keessaa tokko bal’ina weerarichaa, isa “adeemsa achii olii dalga galchuu” jedhu hir’isuuf yaaluudha.
The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing or sneezing.
Kana malees, ‘CDC’n namoonni dhuunfaan, keessumaa erga mana fincaanii dhaqanii booda yookaan xuriin harka irraa sirriimatti yeroo mul’atu, nyaachuudhaan duraafi erga furrii baafatanii, qufaa’anii yookaan haxxiffatanii booda, harka isaanii saamuunaa fi bishaaniin yoo xiqqaate sekoondii 20f akka isaan dhiqatan gorsa.
It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production.
Qulqullessituu harkaa alkooliirraa qopheeffame, kan qabiyyeen alkoolii isaa yoo xiqqaate %60 ta’e, fayyadamuutu gorfama, garuu kun saamuunaafi bishaan qophaa’ee hinjiru yoo ta’edha. Bakkeewwan qulqulleessitootni harkaa gurgurtaadhaaf salphaatti hin argamnetti Dhaabbati Fayyaa Addunyaa bulbula akaakuu lama kan naannootti oomishamuu danda’an dhiyeessa.
In these formulations, the antimicrobial activity arises from ethanol or isopropanol.
Foormulaa kana keessatti, gochoonni jarmii (antimaaykiroobiyaal) ajjeesan itaanolii yookaan aysopiroopaanol irraa argamu.
Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis".
Haayidiroojiin peerooksaayidiin seeliiwwan baakteeriyaa alkoolii keessatti argaman balleessuuf fayyada malee “harka baakteeriyaarraa qulqulleessuuf wanta dammaqinaan fayyadu miti”.
Glycerol is added as a humectant.
Gilaayiserooliin jiidha akka kennuuf itti dabalame.
People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.
Namoonni kunuunsa gargaarsaa kanneen akka yaala dhangala’oo, gargaarsa oksijiinii, fi gargaarsa qaamota miidhaman birootiin hogganamu.
The CDC recommends that those who suspect they carry the virus wear a simple face mask.
‘CDC’n namoonni vaayirichan baadha jedhanii of shakkan akka isaan maaskii fuulaa xiqqoo godhataniif gorsa.
Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.
Extracorporeal membrane oxygenation (ECMO)’iin dadhabbi sirna hargansuu hogganuuf fayyada. Ta’us bu’a qabeessummaan isaa ammas too’annaa jala jira.
Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity.
Qulqullina dhuunfaa fi jireenya fayyaa qabeessa akkasumas sirna nyaataa humna ittisa dhibee dabalutu ajajama.
Supportive treatments may be useful in those with mild symptoms at the early stage of infection.The WHO and Chinese National Health Commission have published recommendations for taking care of people who are hospitalised with COVID-19.
Waldhaansi salphaan namoota mallattoolee sasalphoo sadarkaa jalqaba dhukkubichaatti agarsiisaniif kennamu ni fayyada. Dhaabbanni fayyaa addunyaa fi koomishiiniin fayyaa chaayinaa filannoowwan namoota COVID-19’n qabamanii yaala irra jiran kunuunsuuf oolu qopheessan.
Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.
Ogeessonni sombaa U.S. dhaabbattota hedduurraa raga ba’iinsa yaalii madda bilisaa IBCC qopheessaniiru.
As of April 2020, there is no specific treatment for COVID-19.
Ebla 2020 irraa eegalee, COVID-19 dhaaf daawaan adda ta’e hin jiru.
For symptoms, some medical professionals recommend paracetamol (acetaminophen) over ibuprofen for first-line use.
Mallattoolee dhukkubichaatiif ogeeyyiin fayyaa tokko tokko itti fayyadama yeroo jalqabaatiif iibuuproofiiniirra parastaamoolii (aseetaaminoofiinii) fudhachuu gorsu.
Precautions must be taken to minimise the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation.
Babal’ina vaayirasii hir’isuuf, keessattuu sirna eegumsa fayyaa keessatti yeroo adeemsa uujummoo hargansuu maddisiisu raawwannu of eeggannoowwan godhamuu qaban.
For healthcare professionals caring for people with COVID-19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions and airborne precautions.The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic.
Ogeessota fayyaa namoota COVID-19 qaban wal’aananiif, Wiirtuun To’annaa Qorichaa (CDC) of-eeggannoowwan beekamoo, of-eeggannoowwan wal tuttuqqii fi of-eeggannoowwan wantoota qilleensaan baatamanii irratti dabaluudhaan Kutaa Eerboorni Infeekshin Aayisoleeshin (AIIR) keessa namicha qabame san akka tursan gorsa. ‘CDC’n yeroo weeraraa kanatti itti fayyadama meeshaalee eeggannoo dhuunfaatiif qajeelfamoota tarreessee jira.
The recommended gear is: PPE gown, respirator or facemask, eye protection, and medical gloves.When available, respirators (instead of facemasks) are preferred.
Golgaawwan qaamaa jajjabeeffaman: uffata PPE, meeshaa hargansuuf gargaaru yookaan haguuggaa fuulaa, haguugduu harkaati. Kan argamu taanaan haguugduu fuula caalaa hargansiiftuutu filatama.
N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA).
Meeshaan hargansuu N95 sirna industiriitiif darbe, garuu FDA’n maaskicha Emergency Use Authorisation (EUA) jalatti akka tajaajilu eeyyame.
They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses.
Dhukkubota qilleensaan daddarban akka ittisaniif qophaa’anis qaama baayilojikaala tokkoof faallaa ta’uun tajaajilaaf akka hin oolle godha.
When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.
Maaskiin yeroo hinjirretti Wiirtuun Ittisaa fi To’annaa Dhukkubaa (CDC) golgaa fuulaa yookaan, akka filannoo isa dhumaatti ammoo, aguugduu manatti hojjetame akka godhatan gorsa.
Most cases of COVID-19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are.
Dhukkuboonni KOVID-19 harki caalaan isaanii cimoo fi veentileetarii namaan hojjetu yookaan filannoowwan biraa kan barbaadan miti, dhibbeentaan hangi tokko garuu ni barbaadu.
The type of respiratory support for individuals with COVID-19 related respiratory failure is being actively studied for people in hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure.
Akaakuu rakkoo hargansuu namoota COVID-19’n qabaman muudatu irratti gargaarsa gochuuf namoota hospitaalatti argaman irratti yaalii cimaatu gaggeeffame. Ragaawwan hammataman tokko tokko hambisuudhaan daddarba cimaa keessoo funyaanii fi dhiibbaa daandii qilleensaa karaa geessisa.
Whether either of these two leads to the same benefit for people who are critically ill is not known.
Lamaan isaanii namoota baay’ee dhukkubsataniif bu’aa tokko qabaachuufi dhiisuu isaanii hin beekamne.
Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.Severe cases are most common in older adults (those older than 60 years, and especially those older than 80 years).
Doktoroonni tokko tokko meeshaa hafuura baafachiisu kan qaama namaa keessa galu waliin turuu filatu sababni isaas malli kun ujummoo funyaaniin qaama keessa seensifamu caalaa faffaca’iinsa qaamolee qilleensaa xixiqqoo daangessa. Dhukkubsattoonni haala ammaataa keessa seenan ga’eessota umurii guddaati (warra waggaa 60 olii, fi keessumaa immoo warra waggaa 80 olii).
Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID-19 cases severe enough to require hospitalisation.
Biyyoonni guddatan hedduun tokkoon tokkoon namootaatiif siree mana yaalaa ga’aa hinqaban, kun immoo dhaabbileen fayyaa lakkoofsa namoota COVID-19 dhaan qabamanii dhukkubi itti ammaachuurraa kan ka’e wal’aansa mana yaalaa barbaadan, isa aal tokkoon garmalee ol ka’e keessummeessuudhaaf humna hinqaban.
One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died.
Qorannoon biyya chaayinaa tokko akka argatetti 5 % gara kutaa waldhaansa addaatti seenu, 2.3% gargaarsa tajaajila meeshaa sirna hargansuu barbaadu, 1.4% ni du’u.
In China, approximately 30% of people in hospital with COVID-19 are eventually admitted to ICU.
Chaayinaa keessatti, namoota COVID-19 dhaan qabamanii hospitaala jiran keessaa tilmaamaan %30 dhumarratti gara kutaa kunuunsa cimaatti (ICU) seenu.
Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID-19 and oxygenation becomes increasingly difficult.
Meeshaadhaan hafuura baafachiisuun akka mallattoon hafuura baafannaa dhiphisaa cimaan (ARDS) COVID-19 keessatti uumameen daran walxaxaa ta’aa adeema, ooksijiinii kennuufiinis daran rakkisaa ta’aa adeema.
Ventilators capable of pressure control modes and high PEEP are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax.
Veentileeteroonni humna qilleensaa to’achuu danda’aniifi ‘PEEP’ guddaa qaban dhiyeessii ooksijiinii guddisuufi miidhaafi walitti galuu sombaa balaa veentileeterii waliin walqabate xiqqeessuuf barbaachisoodha.
High PEEP may not be available on older ventilators.
Veentileeteroota moofaa keessa ‘PEEP’ n jiraachuu dhiisuu mala.
Research into potential treatments started in January 2020, and several antiviral drugs are in clinical trials.
Qorannoon qorichoota abdii qaban irratti godhamu Amajjii 2020 keessa eegalame, qorichoonni farra vaayirasii hedduun immoo dhukkubsattootarratti yaalamaa jiru.
Remdesivir appears to be the most promising.
Remdesivir hunda caalaa waan abdii qabu fakkaata.
Although new medications may take until 2021 to develop, several of the medications being tested are already approved for other uses or are already in advanced testing.
Daawaa haaraa qopheessuun hanga 2021 tti turuu malu illee, daawaalee yaalamaa jiran keessaa hedduun isaanii faayidaalee biroodhaaf kan hayyamamanidha yookaan immoo kanumaan dura yaalii olaanaarra jiru.
Antiviral medication may be tried in people with severe disease.
Qorichi farra vaayirasii namoota sadarkaa olaanaan dhukkubsatan irratti yaalamuu danda’a.
The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened.
Dhaabbati Fayyaa Addunyaa namoonni fedha qaban yaalii bu’a qabeessummaafi nagummaa wantoota daawaa ta’uu malan kanaatti akka hirmaataniif yaada dhiyeesse. Abbaan Taayitaa Daawaa Federaalaa akka daawaa yaaliitti dhukkubsattoota lubbuun isaanii balaa hamaarra jiru yookaan saffisaan miidhaman irratti akka yaalamuuf pilaazmaa dandamateef hayyama yeroo gabaabaa kenne.
It has not undergone the clinical studies needed to show it is safe and effective for the disease.
Dhukkubichaaf akka fayyadu qo’annoo kilinikaatiin miti kan mirkanaa’e.
In February 2020, China launched a mobile app to deal with the disease outbreak.
Gurraandhala 2020 keessa, Chaayinaan ka’umsa dhukkuba kanaa qorachuuf mosaajjii bilbila sochootuu gad dhiistee turte.
Users are asked to enter their name and ID number.
Fayyadamtoonni maqaa fi lakkoofsa eenyummaa (ID) isaanii akka galchan gaafataman.
The app is able to detect 'close contact' using surveillance data and therefore a potential risk of infection.
App’chi odeeffannoo sarveellansii irraa argatuun walitti siiquu fi haalota faalamaaf nama saaxilan adda baasa.
Every user can also check the status of three other users.
Fayyadamaan tokko haala fayyadamtoonni biroo sadii keessa jiran sakatta’uu danda’a.
If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.Big data analytics on cellphone data, facial recognition technology, mobile phone tracking and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan and Singapore.
Yoo balaa hamaan argame app’chi akka namoota irraa addatti of baafnu qofa miti kan himu, hoggantoota fayyaa naannawatti argaman beeksisa. Qorannaa odeeffannoo bilbilaa, teeknoolojii fuula adda baasu, bilbila moobaayilaa too’achuu fi odeeffannoo nam-tolcheen namoota dhukkubaan qabamanii fi namoota isaan Kooriyaa kibbaa, Taayiwaanii fi Singaapooritti qunnaman adda baasuuf fayyada.
In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus.
Bitootessa 2020 keessa mootummaan Israa’el dhaabbileen nageenyaa bilbila moobaayilaa namoota vaayirasii koroonaa qabanii akka hordofan dandeessise.
The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens.
Adabbichi kan kennamu yeroo turtii adda baafamuu irratti dhiibbaa uumuuf akkasumas namoota lammiilee dhukkubichaan qabaman tuttuquu danda’an ittisuuf.
Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, in order to research and prevent the spread of the virus.
Bitootessa 2020 keessas, Teeleekoomiin Dooch, tatamsa’ina vaayiresichaa qorachuu fi ittisuuf Dhaabbata Rooberti Kooch, eejensii mootummaa federaalaa Jarmaniitiif ragaa bakkee bilbilaa walta’aa qoode.
Russia deployed facial recognition technology to detect quarantine breakers.
Namoota seera adda-of baasuu cabsan adda baasuuf Raashaan teeknooloojii fuula namaa qalbeeffatu hojiitti bobbaaste.
Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway".
koomishiinarri fayyaa naannoo Xaaliyaan Giulio Gallera jedhanitti ummanni 40% ammas sochii itti fufee akka jiru opereetaroota bilbila harkaa irraa akka odeeffatan himan.
German government conducted a 48 hours weekend hackathon with more than 42.000 participants.
Mootummaan Jarman guyyaa sanbataa fi dilbataa dorgommii sa’aatii 48 fudhatee fi namoota 42,000 hirmaachise gaggeesse.
Also the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.
Akkasumas, Pirezidaantiin Istooniyaa, Keeristii Kaaljuuleeyid, tatamsa’ina vaayirasii koroonaa irratti guutummaan addunyaa fala haaraa akka barbaaduuf waamicha godhan.
Individuals may experience distress from quarantine, travel restrictions, side effects of treatment or fear of the infection itself.
Namoonni dhuunfaa adda of baasuu, qoqqobbii imalaa, dhiibbaa cinaa wal’aansaa yookaan faalama sodaachuu irraa kan ka’e dhiphachuu malu.
BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress and an economic downturn are a perfect storm to harm people's mental health and wellbeing."
BBC’n jecha Rory O'Connor akkanatti kaa’e “dabaluun addaan fageenya hawaasaa, kophummaa, faalamuu fayyaa, cinqamuu fi diinagdeen hubamuun fayyaa sammuu qaama namaa irratti miidhaa fida.”
The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold.
Dhukkubi kun laafaa mallattoolee muraasa agarsiisu yookaan mallattoo hinqabne ta’uu mala, kan dhibeewwan hafuuraan darban beekamoo, kanneen akka qufaa isa fakkeessan.
Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover.
Warri dhukkubni itti hin cimin yeroo turban lamaa keessatti fayyu, warri dhukkubichi itti cime torbanoota sadii hanga jahaa itti fudhachuu mala.
Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.In some people, COVID-19 may affect the lungs causing pneumonia.
Daataawwan vaayirasii walfakkaataa irra dhaabachuun dubartoonni ulfaa dhibee COVID-19 irra jireessaan hubamoo ta’u, garuu daataan COVID-19 ni hir’ata,dhibeen COVID-19 dhukkuba sombaa fiduudhaan somba hubuu danda’a.
In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock or multi-organ failure.
Warreen dhukkubichi sadarkaa olaanaan itti hammaate irratti COVID-19 sirna hargansuu hubuudhaan, qaamota biroos miidhuun saffisaan gara acute respiratory distress syndrome (ARDS)’tti ce’uu danda’a.
Complications associated with COVID-19 include sepsis, abnormal clotting and damage to the heart, kidneys and liver.
Burjaaja’ummaan COVID-19 wajjiin walqabatu seepsiisii, miidhama onnee, kale fi tiruu hin baratamin fa’a hammata.
Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group.
Dhukkubsattoota COVID-19 dhaan hospitaala seenan keessaa dhibbeentaan 6 kantaruu dhiigaa seeraan ala ta’e, keessumaa yeroo pirootiroombiinii ol ka’aa akka qaban, garee kana keessaa dhibbeentaan 4 ammoo kalee sirriitti hin dalagne akka qaban ibsame.
Approximately 20-30% of people who present with COVID-19 demonstrate elevated liver enzymes (transaminases).
Tilmaamaan namoonni COVID-19 qaban dhibbeentaa 20 hanga 30 tti eenzaayimii tiruu ol ka’aa (tiraansaaminaasis) agarsiisu.
According to the same report, the median time between onset of symptoms and death was ten days, with five being spent hospitalised.
Akka gabaasa walfakkaatuutti, dheerinni yeroo inni giddugaleessaa mul’achuu mallattootii fi du’a gidduu jiru guyyoota kudhanidha, isa keessaa shan mana yaalaa keessatti kan dabarfamu.
However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.
Haa ta’u malee, dhukkubsattoonni gara ICU tti darban giddugaleessaan yeroo guyyaa torbaa deddeebii hospitaalaa fi du’a gidduutti qabu.
In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.
Qo’annoo dhukkubsattoota gara jalqabaa irratti adeemsifame keessatti, giddugaleessi dheerina yeroo mallattoo jalqabaa agarsiisuudhaa hanga du’aatti jiru guyyoota 14 ture, guutummaan dheerina yeroo isaa immoo guyyaa jahaa hanga 41 ti.
In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.
Qorannoo National Health Commission (NHC) chaayinaa keessatti akka agarsiisutti dhiira 2.8% fi dubara 1.7%tu du’a.
Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs.
Qorannoon Histopatoologii somba nama du’ee irraa fudhatamu akka agarsiisutti somba lamaan keessatti manca’iinsi sombaa babal’achuu mul’isa.
Viral cytopathic changes were observed in the pneumocytes.
Jijjiiramni Saayitoopaatikii vaayirasii niimoosaayitii keessatti argame.
The lung picture resembled acute respiratory distress syndrome (ARDS).
Suuraan sombaa sun rakkoo hafuura baafachuu dadhabuu isa hamaa (ARDS) fakkaate.
In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.
Du’a namootaa Koomishiinii Fayyaa Biyyoolessaa Chaayinaatiin gabaafame keessaa dhibbeentaan 11.8 miidhaan onnee olka’uu hanga tirooppooniinii yookaan onneen hojii dhaabuu irraa ka’e ta’uu hubachiifame.
According to March data from the United States, 89% of those hospitalised had preexisting conditions.Availability of medical resources and the socioeconomics of a region may also affect mortality.
Akka ragaa bitootessa Yunaayitid Isteetiitti, namoota hospitaala seenan keessaa 89% mallattoo baratamaa qaba. Akkasumas hammi namoota du’anii qabeenya meeshaalee fayya fi diinagdee biyyaa irratti hundaa’a.
Estimates of the mortality from the condition vary because of those regional differences, but also because of methodological difficulties.
Tilmaamni du’aa garaagarummaa naannolee irratti hundaa’ee garaagarummaa qaba, akkasumas ciminni tooftaalee sababa ni ta’a.
The under-counting of mild cases can cause the mortality rate to be overestimated.
Dhibeewwan ammaatoo hintaane hammaa gaditti lakkaa’uun hammi du’aa hammaa olitti akka tilmaamamu taasisuu danda’a.
However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.
Haa ta’u malee, du’i namootaa sababa qabamuu kanaan duraa ta’uun isaa saffisi du’a yeroo ammaa hammaa gaditti yaadame jechuudha.
Smokers were 1.4 times more likely to have severe symptoms of COVID-19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.Concerns have been raised about long-term sequelae of the disease.
Namoonni tamboo xuuxan carraan isaan mallattoolee COVID-19 hamaa agarsiisan warra hinxuuxne caalaa harka 1.4 dha, tilmaamaan immoo carraan kunuunsa cimaa barbaachuu yookaan du’uu isaanii hinxuuxne caalaa harka 2.4 guddata. Rakkoo dhukkubichi yeroo dheeraa keessa fidu ilaalchisee yaaddoowwan jiran kaafamaniiru.
The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.
Hoggantoonni hospitaala hoong koong qabiyyee sombaa namoota dhukkubsatanii fayyanii keessatti copha 20% hanga 30% ta’u argatan.
This may also lead to post-intensive care syndrome following recovery.
Dhukkubicharraa fayyuutti aansee wanti kun gara mallattoo kunuunsa addaa boodaatti geessuu danda’a.
As of March 2020, it was unknown if past infection provides effective and long-term immunity in people who recover from the disease.
Akka bitootessa 2020tti namoonni dhukkubsatanii fayyan madiinummaan isaanii ni deebi’aaa fi yeroo dheeraa turuu danda’aa irratti wanti beekame hin jiru.
Immunity is seen as likely, based on the behaviour of other coronaviruses, but cases in which recovery from COVID-19 have been followed by positive tests for coronavirus at a later date have been reported.
Madiinummaan akka amala vaayirasii koroonaa irratti hundaa’a, garuu namoonni COVID-19 irraa fayyanii ammas qorannoon isaanii pozatiivii ta’e gabaafame.
These cases are believed to be worsening of a lingering infection rather than re-infection.
Haallonni kunniin irra deebiin dhukkubaan qabamuu irra dhukkuba dhaabuun hamaa akka ta’etti amanama.
The virus is thought to be natural and have an animal origin, through spillover infection.
Vaayirasichi uumamaan kan jiruu fi bineensota irraa dhufe jedhamee yaadama.
The actual origin is unknown, but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission.
Maddi isaa inni dhugaan hinbeekamne, garuu Muddee 2019 tti faffaca’iinsi faalamaa guutummaan guutuutti haala jechuun danda’amuun namaa namatti darbaa ture.
A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.
Qorannaan namoota calqaba COVID-19 qabaman 41 irratti gaggeeffame fi Amajjii 2020 maxxanfame akka ifoomsetti guyyaan jalqaba itti mallattoon mul’ate Muddee 1 2019 dha.
Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.
Mallattoon jalqabaa WHO’dhaan kan maxxanfame muddee 8, 2019.
Several measures are commonly used to quantify mortality.
Lakkoofsa namoota du’anii himuuf tarkaanfiiwwan hedduutu fudhatama.
These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since initial outbreak and population characteristics such as age, sex and overall health.
Lakkoofsi kun biyya, yeroo fi hamma qorachuu, qulqullina sirna fayyaa, filannoowwan yaalaa, umrii saalaa fi fayyaa waliigalaa irratti hundaa’a.
In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval.
2019 gara dhumaatti, Dhaabbati Fayyaa Addunyaa koodiiwwan dhukkubaa ICD-10 yeroo muddamaa du’a faalama SARS-CoV-2 laabiraatooriidhaan mirkanaa’een dhufeef U07.1, akkasumas du’a mallattoolee dhukkubaa COVID-19 kan faalama SARS-CoV-2 laabiraatooriidhaan hin mirkanoofneen dhufeef U07.2 ramade. Reeshiyoon du’a dhukkubsattootatti madaalu wal irraa fageenya yeroo murtaa’aa keessatti lakkoofsi warra du’anii lakkoofsa namoota mallattoon dhukkubichaa irratti argameef qoodamuu isaa agarsiisa.
Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.9% (153,822/2,240,191) as of 17 April 2020.
Odeeffannoo Yuunivarsiitii Joon Hoopkiinsi irratti hundaa’uun, akka ebla 17,2020tti reeshiyoon dhukkubsattoota keessaa kanneen du’anii 6.9% (153,822/2,240,191) dha.
The number varies by region.Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease.
Lakkoofsi naannoo naannootti garaagarummaa qaba. Shallaggiiwwan biraa case fatality rate (CFR) hammatan, kan parsantii namoota mallattoon dhibee isaani adda bahee du’anii agarsiisu fi infection fatality rate (IFR), kan namoota mallattoon dhibee isaanii adda bahee fi osoo adda hin bahin du’an.
These statistics are not time bound and follow a specific population from infection through case resolution.
Odeeffannoon kun kan yeroo irratti hundaa’uu fi hawaasa murtaa’e qofa hordofu miti.
While not all infected people develop antibodies, the presence of antibodies may provide information about how many people have been infected.
Namoonni faalaman hundi pirootiinii dhiigaa dhukkuba ittisu horachuu yoo baatan illee, jiraachuun pirootiiniiwwan kanniinii lakkoofsa namoota faalamanii ilaalchisee odeeffannoo kennuu malu.
In the epicentre of the outbreak in Italy, Castiglione d'Adda, a small village of 4600, 80 (1.7%) are already dead.
Giddugaleessa jalqabbii dhukkubichaa biyya Xaaliyaanii keessatti, ganda xiqqoo Kaastiiliyoonee Dii Aadaa uummata 4600 qabdu keessatti namoonni 80 (%1.7) du’anii jiru.
In Gangelt, the disease was spread by Carnival festivals, and spread to younger people, causing a relatively lower mortality, and not all COVID-19 deaths may have been formally classified as such.
Gaangelt keessatti, dhukkubichi feestivaala kaarnivaaliin baballate, gara dargaggootaattis daddarbe, du’a gadi bu’aaf galmeessisaa jira, akkasumas du’I COVID-19 hundi akka kanatti adda ba’eera ta’uu danda’a.
Furthermore, the German health system has not been overwhelmed.
Caalaatti sirna fayyaa Jarmanitti humnaa ol hin taane.
In the Netherlands, about 3% may have antibodies, as assessed from blood donors.
Neezerlaan keessatti, akka namoota dhiiga arjooman irraa tilmaamametti gara 3%tu aantiibodii qaba.
69 (0.004% of the population) have been confirmed to have died from COVID-19.
69 (baay’ina uummatichaa keessaa dhibbeentaan 0.004) COVID-19 irraa kan ka’e du’uu isaanii mirkaneeffameera.
The impact of the pandemic and its mortality rate are different for men and women.
Miidhaan weerarichi geessisuu fi hammi ajjeechaa isaa dhiiraa fi dubara irratti garaagarummaa qaba.
Mortality is higher in men in studies conducted in China and Italy.
Qorannoowwan Chaayinaa fi Xaaliyaanii keessatti adeemsifaman keessatti du’i dhiirotaa olaanaadha.
The highest risk for men is in their 50s, with the gap between men and women closing only at 90.
Dhirootaaf balaa olaanaan waggaa 50 keessa yoo jiraatanidha, garaagarummaan dhiiraa fi dhalaa waggaa 90 tti bada.
In China, the death rate was 2.8 percent for men and 1.7 percent for women.
Chaayinaa keessatti hammi du’a dhiiraa parsantii 2.8 fi kan dubaraa dhibbeentaa 1.7 dha.
The exact reasons for this sex-difference is not known, but genetic and behavioural factors could be a reason.
Sababii sirriin garaagarummaa kornaayaa kun hin beekamu, garuu garaagarummaan jiiniitiifi amalaa sababa ta’uu danda’a.
Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.
Garaagarummaan madiinumma saala irratti hundaa’e, sigaaraa aarsuun dubartoota irratti xiqqaachuun fi dhiironni sadarkaa dargagummaatti dubartoota caalaa amala cinqamuu agarsiisuun du’aatiin dhiiraa kan dubartootaa caalaa akka dabalu taasise.
In Europe, 57% of the infected individuals were men and 72% of those died with COVID-19 were men.
Awurooppaa keessatti namoota faalaman keessaa dhibbeentaan 57 dhiirota turan, namoota COVID-19 dhaan lubbuun isaanii darbe keessaa ammoo dhibbeentaan 72 dhiirota.
As of April 2020, the US government is not tracking sex-related data of COVID-19 infections.
Akka ebla 2020tti mootummaan US dhukkubsattoota sababa walqunnamatii saalaatiin COVID-19’n qabaman hin arganne.
Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
Akka qorannoon agarsiisutti dhukkubni vaayirasii kanneen akka Iiboolaa, HIV, infuluweenzaa fi SARS miidhaan isaan dhiiraa fi dubara irraan gahan garaagarummaa qaba.
A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.
Hojjattoonni fayyaa parsantiin hedduun, keessattu narsoonni, dubartoota, kanaafis carraa dhukkubaaf saaxilamuu olaanaa qabu.
The World Health Organization announced on 11 February 2020 that the official name of the disease would be "COVID-19".
Maqaan seeraa dhukkubichaa "COVID-19" akka ta’u dhaabbanni fayyaa addunyaa Gurraandhala 11 2020 murteesse.
WHO chief Tedros Adhanom Ghebreyesus explained that CO stands for corona, VI for virus, D for disease, and 19 for when the outbreak was first identified: 31 December 2019.
Akka hogganaan dhaabbata fayyaa addunyaa Tedros Adhanom Ghebreyesus ibsanitti CO’n corona bakka bu’a, VI’n virus bakka bu’a, D’n disease bakka yoo bu’u, 19 yeroo dhukkubichi jalqaba itti eegale, muddee 31, 2019 bakka bu’a.
The name had been chosen to avoid references to a specific geographical location (e.g. China), animal species or group of people, in line with international recommendations for naming aimed at preventing stigmatisation.The virus that causes COVID-19 is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Maqaan isaa kan filatame kallattii murtaa’e irratti akka hin fudhatamne hamisuuf (fakkeenyaaf chaayinaa), gosa bineensotaa yookaan garee namootaattis akka hin murtoofneef tooftaalee maqeessuu biyyoolessaatti fayyadamuun istiigmatayizeeshii ittisuudhaaf kan moggaafameedha. Vaayirasiin COVID-19 fidu severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) jedhamee moggaafameef.
The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
Dhaabbanni Fayyaa Addunyaa quunnamtii uummataa keessatti “vaayirasii COVID-19” fi “vaayirasii COVID-19 fidu” dabalataan fayyadama.
Both the disease and virus are commonly referred to as "coronavirus".
Vaayirasichii fi dhukkubichis lamaanuu bakka tokkotti “koroonaa vaayiras” jedhmu.
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus".
Yeroo dhukkubichi Wuhaan, Chaayinaa keessatti eegale keessatti, vaayirasichis dhukkubichis “koroonaa vaayiras” fi “Koroonaa vaayirasii Wuhaan” jechuun beekamu turan.
In January 2020, WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease in accordance with 2015 guidance against using locations in disease and virus names.
Amajjii 2020tti, dhaabbanni fayyaa addunyaa qajelfama bara 2015 irratti hundaa’uun fi maqaa fi naannoo itti argamu irratti hundaa’uun maqaa 2019-nCov fi 2019-nCov cimaa jedhamu dhiheessee.
The official names COVID-19 and SARS-CoV-2 were issued on 11 February 2020.
Maqaaleen seeraa COVID-19 fi SARS-CoV-2 Gurraandhala 11, 2020 itti moogafame.
Due to capacity limitations in the standard supply chains, some digital manufacturers are printing healthcare material such as nasal swabs and ventilator parts.
Hanqina humnaa sirna dhiheessaa keessa jiruun dhaabbileen oomisha dijiitaalaa tokko tokko meeshaalee fayyaa kanneen akka qulqulleessituu funyaanii fi veentileetarii oomishaa jiru.
In one example, when an Italian hospital urgently required a ventilator valve, and the supplier was unable to deliver in the timescale required, a local startup reverse-engineered and printed the required 100 valves overnight.
Fakkeenya tokko keessatti, hospitaalli biyya Xaaliyaanii tokko yemmuu inni atattamaan vaalvii veentileetaraa barbaadee dhiyeessaan yeroo barbaadamu keessatti dhiyeessuu dadhabe, warshaan naannoo sanaa tokko vaalvii warshaa biraa qorachuun halkan tokkotti vaalviiwwan barbaachisan 100 oomishee bule.
After the initial outbreak of COVID-19, conspiracy theories, misinformation and disinformation emerged regarding the origin, scale, prevention, treatment and other aspects of the disease and rapidly spread online.
Ka’umsa jalqabaa COVID-19 booda, katabbiiwwan to’annoo, hundeeffamasaan walqabatee odeeffannoo dhabuu, iskeelii, ittisa, yaalii fi gama dhukkubichaa biroo fi faffaca’iinsa ariitii.
Humans appear to be capable of spreading the virus to some other animals.
Namni bineensa biraattis dhukkubicha daddabarsuu akka danda’u irra gahamee jira.
The study failed to find evidence of viral replication in pigs, ducks, and chickens.
Qorannochi booyyee, daakiyyee fi lukkuu keessatti vaayirasiin wal horuu isaatiif ragaa argachuu hindandeenye.
No medications or vaccine is approved to treat the disease.
Dhukkubicha yaaluuf daawaan yookaan talaalliin mirkanaa’ee hinjiru.
International research on vaccines and medicines in COVID-19 are underway by government organisations, academic groups and industry researchers.
Talaallii fi daawaa COVID-19 irratti qo’annoon idil addunyaa dhaabbilee mootummaa, gareewwan hayyootaa fi qorattoota indaastiriitiin adeemsifamaa jira.
In March, the World Health Organization initiated the "SOLIDARITY Trial" to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
Bitootessa keessa, bu’aa yaalii farra vaayirasii qophaa’ee jiruu, kanneen bu’a-qabeessummaan isaanii olaanaadha jedhamanii abdatamanii gamaaggamuuf Dhaabbati Fayyaa Addunyaa “Yaalii TOKKUMMAA” eegale.
There is no available vaccine, but various agencies are actively developing vaccine candidates.
Talaalli argame hin jiru, garuu dhaabbileen hedduun talaallii isaa irratti hojjachaa jiru.
Previous work on SARS-CoV is being utilised because SARS-CoV and SARS-CoV-2 both use the ACE2 receptor to enter human cells.
Qorannoon kanaan dura SARS-CoV irratti adeemsifame dhimma itti ba’amaa jira, sababiin isaas SARS-CoV fi SARS-CoV-2n lachan isaanii risaptarii ACE2 fayyadamuudhaan seeliiwwan namaa seenu.
There are three vaccination strategies being investigated.
Malawwan talaallii sadiitu qoratamaa jiru.
First, researchers aim to build a whole virus vaccine.
Jalqaba, qorattoonni talaallii vaayrasii guutuu hojjachuuf karoorfatan.
The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID-19.
Itti fayyadamni vaayirasii kanaa, kan humni isaa laafes ta’e du’aan isaa, deebii dandamannaa qaamni namaa faalama haaraa COVID-19 tti utuu yeroo hin fudhatin agarsiisu keessaa baasuu irratti xiyyeeffata.
A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus.
Malli lammaffaan, talaalliiwwan qaamolee jaloo, talaallii malli dhukkuba ittisuu akka inni qaamolee jaloo vaayiresichaa adda baafatuuf gargaaru uumuudha.
In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor.
SARS-CoV-2 keessatti, qo’annoon akkanaa pirootiinii essi-ispaayikii (S-spike) isa vaayirasichi akka riseeptarii eenzaayimii ACE2 keessa seenuuf gargaaru irratti xiyyeeffata.
A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination).
Tooftaan sadaffaan talaallii nucleic acid (talaallii DNA fi RNA, tooftaa jalqabaa talaallii uumuu).
Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle.
Talaalliiwwan namarratti yaalaman kanneen malawwan kanniin irraa maddan sababoota nageenyaatii fi bu’a qabeessummaatiif jedhanii qoratamuu qabu. Bitootessa 16, 2020 yaaliin talaallii dhukkubsataa irrattii inni jalqabaa Siyaatil keessatti namoota fedhiidhaan itti hirmaatan afur irratti eegalame.
The vaccine contains a harmless genetic code copied from the virus that causes the disease.Antibody dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.
Talaalliin jeneetik koodii miidhaa hin qabne kan vaayirasicha dhibee fidu irraa fudhatame of keessaa qaba. Fooyya’iinsi farra qaama alaagaa uumamaa irratti hundaa’e kan talaallii SARS-COV-2 oomishuuf oolu akka dhiibbaa cimaatti ilaalama. Garuu kun mormisiisaadha.
There are more than 300 active clinical trials underway as of April 2020.
Akka ebla 2020tti yaaliiwaan 300 caalaan kilinika keessatti taasifamaa jiru.
Seven trials were evaluating already approved treatments for malaria, including four studies on hydroxychloroquine or chloroquine.
Yaaliiwwan torba, qorannoowwan afur haadirooksiikiloorookuwiinii yookaan kiloorookuwiinii irratti adeemsifaman dabalatee, qorichoota busaa hanga ammaatti mirkaneeffaman qeeqaa turan.
Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.
Qorannoowwan Chaayinaa harki caalaan isaanii sababa gabaasa xumura Eblaarraa kan ka’e biyyoota hedduu keessatti remdesivir irratti yaaliiwwan sagal marsaa III qaban wajjin qoricha farra vaayirasii deebisanii kaayyoo biraatiif hojjechuu irratti xiyyeeffatu.
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020.Several existing antiviral medications are being evaluated for treatment of COVID-19, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.
Adeemsi talaallii fi qoricha COVID-19 uumuu kilinika keessa jira. Akka ebla 2020tti qorichoonni farra vaayirasii kanaan dura jiran kannen akka remdesiviir, kiloorookiin fi haydirooksiikiloorookiin, lopinaavir/ riitonaaviir fi lopinaavir/ riitonaaviir interferoon wajjiin walitti makamuun yaala COVID-19’tiif qoratamanii jiru.
There is tentative evidence for efficacy by remdesivir, as of March 2020.
Ragaan dhaabbataa hin taane kan Reemdesiivir bitootessa 2020 dhiheesse jira.
Clinical improvement was observed in patients treated with compassionate-use remdesivir.
Dhukkubsattoota dhimmamanii ‘remdesivir’ fayyadaman irratti mallattoon fooyya’iinsaa mul’atee jira.
Phase III clinical trials are being conducted in the US, China and Italy.Chloroquine, previously used to treat malaria, was studied in China in February 2020, with preliminary results.
Yaalii kilinikaa sadaffaan US, Chaayinaa fi Xaaliyaaniitti gaggeeffame. Kiloorookuwiin duraan malariyaa waldhaanuuf itti fayyadamnu kan qo’atame Chaayinaatti Gurraandhala 2020 dha.
However, there are calls for peer review of the research.
Gama biraatiin irra durduubee qorannootiif waamichatu jira.
Korean and Chinese Health Authorities recommend the use of chloroquine.
Aangawoonni fayyaa kooriyaa fi chaayinaa bu’a qabeessummaa kiloorookuwiinii himaniiru.
However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal.
Haa ta’u malee, Dhaabbati Vaayirooloojii Wuhaan, guyyaa guyyaatti hamma fudhannaa giraama tokko utuma gorsuu, hammi fudhannaa harka lama yoo ta’e balaa hamaa hanga du’aatti nama geessuu danda’u qabaachuu isaa yaadachiisa.
On 28 March 2020, the FDA issued an emergency use authorisation for hydroxychloroquine and chloroquine at the discretion of physicians treating people with COVID-19.The Chinese 7th edition guidelines also include interferon, ribavirin or umifenovir for use against COVID-19.
Bitootessa 28, 2020tti kunuunsa namoota COVID-19 qabamaniif FDA’n haydirooksikiloorookiin fi kiloorookiin hayyama gaafata. Maxxansi 7ffaan qajeelfama chaayinootaas interfiroonii, riibaviriinii yookaan yumiifenoviir ittisa COVID-19’f itti fayyadama.
Preliminary data indicate that high doses of ribavirin are necessary to inhibit SARS-CoV-2 in vitro.
Odeeffannoon wixineerra jiru akka ibsutti riibaviriin humnaa ol fayyadamuun dhuujummoo qorannaa keessatti amalli SARS-CoV-2 akka mul’atu taasisa.
Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor.
Naataazozaniid qorannoo SARS-CoV-2’tiif dabalataan ajajama. Akka qorannoowwan agarsiisanitti pirotiinii qopheessuuf oolu transmembrane protease serine 2 (TMPRSS2)’n fudhattuu ACE2 wajjiin seensa SARS-CoV-2’tiif muteessadha.
The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID-19 treatment.
Qorannoowwan kiloorookuwiinii fi haayidirookiloorookuwiinii aziitiroomaayisiinii qaban yookaan hinqabne rakkoowwan guguddoo, kan hawaasi fayyaa utuu qorannoon dabalataa irratti hin adeemsifamin akka qorichaatti akka hinfudhanne isaan taasise qabu. Oseltaamiviir ‘vaayitiroo’ keessatti SARS-CoV-2 hin ittisu, COVID-19 wal’aanuu keessattis ga’ee beekamaa hinqabu.
Cytokine storm can be a complication in the later stages of severe COVID-19.
Buubbeen saayitookin (cytokine storm) dhibee dabalataa sadarkaalee dhumaa COVID-19 isa ammaataa ta’uu danda’a.
There is evidence that hydroxychloroquine may have anti-cytokine storm properties.Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
Haaydrookilooriiniin amaloota farra saaytookiinii qabaachuu akka danda’u ragaan jira. Erga qorannoon salphaan gaggeeffameen booda Tocilizumab’iin qajeelfama yaalaa koomishiinii fayyaa biyyaalessa chaayinaatti dabalee jira.
It is undergoing a phase 2 non randomised test at the national level in Italy after showing positive results in people with severe disease.
Erga nama sadarkaa hamaatti dhukkubsate irratti mallattoon argameen booda Xaaliyaanitti qorannoon marsaa 2ffaan sadarkaa biyyaalessaatti gaggeeffamaa jira.
Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.
Qorannoo dhangala’aa ferritinii dhiigaa wajjiin walitti makamuun saaytookinii adda baasuuf oola, kana jechuun adeemsa namoota dhukkubsatan tokko tokko ni ajjeesa jedhamee yaadamu hambisa.
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
Fudhataan faallessaa interluukiin – 6 FDA’n kan mirkanaa’e qo’annoo yaalaa gosa mallattoo stirooyidii saayirookiinii duraa sababa garaagaraatiin dhufu yaala seelii CAR T bara 2017tti.
To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS.
Ammatti ragaan qindaa’aan toolikizumaab yaala CRS’f ni oola jedhu hin jiru.